J. Lietzau

Phase II trial with dose titration of paclitaxel for the therapy of human immunodeficiency virus-associated Kaposi's sarcoma.

W. Wilson, S. Steinberg, S. Broder, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

CD4 count and the risk for death in patients infected with HIV receiving antiretroviral therapy.

A. Tsiatis, S. Steinberg, D. Venzon, 1991, Annals of internal medicine.

A randomized pilot study of alternating or simultaneous zidovudine and didanosine therapy in patients with symptomatic human immunodeficiency virus infection.

S. Steinberg, H. Mitsuya, O. Brawley, 1994, The Journal of infectious diseases.

Parameters affecting the development of non-Hodgkin's lymphoma in patients with severe human immunodeficiency virus infection receiving antiretroviral therapy.

D. Venzon, S. Broder, J. Karp, 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Fluorometric determination of 2'-beta-fluoro-2',3'-dideoxyadenosine 5'-triphosphate, the active metabolite of a new anti-human immunodeficiency virus drug, in human lymphocytes.

R. Yarchoan, J. Kelley, L. Welles, 2001, Analytical biochemistry.

Treatment of HIV-associated Kaposi's sarcoma with paclitaxel

W. Wilson, S. Broder, I. Feuerstein, 1995, The Lancet.

Effect of combination therapy with zidovudine and didanosine on neuropsychological functioning in patients with symptomatic HIV disease: a comparison of simultaneous and alternating regimens

H. Mitsuya, S. Broder, R. Yarchoan, 1997, AIDS.